| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cef4f341fe4f2caf061611a818576e40 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-227
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 |
| filingDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0f1d474a2c90649f077f87caae2d22c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_203b977a0ada242871edf679c614cef7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb5b142cd14c3899221ac21b0379f620
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36846261cb4c739262c38c3ea4c379c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_faccc8103fc377598667e8009b04a379 |
| publicationDate |
2017-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2646776-T3 |
| titleOfInvention |
New polymorphic crystalline forms of 5- (2 - {[6- (2,2-difluoro-2-phenylethoxy) hexyl] amino} -1- (R) -hydroxyethyl) -8-hydroxyquinoline-2 (1H) -one as beta2 adrenergic receptor agonist |
| abstract |
A pharmaceutical composition comprising a crystalline polymorph of 5- (2 - {[6- (2,2-difluoro-2-phenylethoxy) hexyl] amino} -1- (R) -hydroxyethyl) -8-hydroxyquinoline- 2 (1H) -one and a pharmaceutically acceptable carrier, in which the crystalline polymorph is a polymorph hydrate and the polymorph hydrate has: a) a powder X-ray diffraction pattern (XRPD) with peaks at 13.3, 16 , 1 and 19.2 degrees 2θ (± 0.1 degrees 2θ); and / or b) a differential scanning calorimetry (DSC) curve showing a first endothermia in the range of 75-120 ° C (± 5 ° C) and a second endothermia with a start at 190 ° C (± 1 ° C ). |
| priorityDate |
2012-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |